UB Paderborn / Katalog / Suche / in CDI

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

The Lancet (British edition), 2013-03, Vol.381 (9868), p.735-743

2013

Link zum Volltext

Verfügbarkeit prüfen

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

The Lancet (British edition), 2015-06, Vol.385 (9987), p.2606-2615

2015

Link zum Volltext

Verfügbarkeit prüfen

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Clinical infectious diseases, 2015-08, Vol.61 (3), p.403-408

2015

Link zum Volltext

Verfügbarkeit prüfen

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

AIDS (London), 2011-06, Vol.25 (10), p.1271-1280

2011

Link zum Volltext

Verfügbarkeit prüfen

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

The Lancet infectious diseases, 2015-07, Vol.15 (7), p.785-792

2015

Link zum Volltext

Verfügbarkeit prüfen

Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study

PloS one, 2020-08, Vol.15 (8), p.e0237739-e0237739

2020

Link zum Volltext

Verfügbarkeit prüfen

Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018

BMC infectious diseases, 2022-04, Vol.22 (1), p.379-379, Article 379

2022

Link zum Volltext

Verfügbarkeit prüfen

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption

PloS one, 2019-01, Vol.14 (1), p.e0210965-e0210965

2019

Link zum Volltext

Verfügbarkeit prüfen

Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144

Viruses, 2023-06, Vol.15 (6), p.1350

2023

Link zum Volltext

Verfügbarkeit prüfen

Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Switch Scenarios in HIV-Infected Patients

Journal of clinical medicine, 2021-08, Vol.10 (16), p.3456

2021

Link zum Volltext

Verfügbarkeit prüfen

HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation

Frontiers in immunology, 2018-07, Vol.9, p.1673-1673

2018

Link zum Volltext

Verfügbarkeit prüfen

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

Journal for immunotherapy of cancer, 2021-03, Vol.9 (3), p.e001664

2021

Link zum Volltext

Verfügbarkeit prüfen

Long-term efficacy and safety of nevirapine-containing regimens in virologically suppressed patients: a 17-year follow up

HIV research & clinical practice, 2019-11, Vol.20 (6), p.151-155

2019

Link zum Volltext

Verfügbarkeit prüfen

Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression

AIDS research and human retroviruses, 2014-10, Vol.30 (10), p.984

2014

Link zum Volltext

Verfügbarkeit prüfen

Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV

Expert review of anti-infective therapy, 2017-03, Vol.15 (3), p.195-209

2017

Link zum Volltext

Verfügbarkeit prüfen

Switching strategies in the recent era of antiretroviral therapy

Expert review of clinical pharmacology, 2019-03, Vol.12 (3), p.235-247

2019

Link zum Volltext

Verfügbarkeit prüfen

Lack of benefit with omega-3 fatty acid supplementation in HIV patients: A randomized pilot study

HIV research & clinical practice, 2019-05, Vol.20 (3), p.99-105

2019

Link zum Volltext

Verfügbarkeit prüfen

Switch strategies in 2014

BMC infectious diseases, 2014-05, Vol.14 (S2), p.S4-S4, Article S4

Podzamczer, Daniel

2014

Link zum Volltext

Verfügbarkeit prüfen

Lipid metabolism and cardiovascular risk in HIV infection: new perspectives and the role of nevirapine

AIDS reviews, 2013-10, Vol.15 (4), p.195-203

Podzamczer, Daniel

2013

Link zum Volltext

Verfügbarkeit prüfen

Acute inflammatory demyelinating polyneuropathy following interruption of antiretroviral treatment and HIV rebound

Journal of antimicrobial chemotherapy, 2020-05, Vol.75 (5), p.1356-1357

2020

Link zum Volltext

Verfügbarkeit prüfen

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

The Lancet (British edition), 2017-11, Vol.390 (10107), p.2063-2072

2017

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study

Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption

Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144

Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Switch Scenarios in HIV-Infected Patients

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

Long-term efficacy and safety of nevirapine-containing regimens in virologically suppressed patients: a 17-year follow up

Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression

Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

Switching strategies in the recent era of antiretroviral therapy

Lack of benefit with omega-3 fatty acid supplementation in HIV patients: A randomized pilot study

Switch strategies in 2014

Lipid metabolism and cardiovascular risk in HIV infection: new perspectives and the role of nevirapine

Acute inflammatory demyelinating polyneuropathy following interruption of antiretroviral treatment and HIV rebound

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Suchergebnisse filtern